Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dynamic effects of radioactive iodine therapy on gut microbiota and metabolites in patients with papillary thyroid cancer.

Microbiology spectrum·2026

Same author

Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment.

Cell·2026

Same author

OptoRibo-seq for spatiotemporally resolved mapping of the local protein translatome.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity.

The Journal of experimental medicine·2026

Same author

Degrade to Display: Coupling Checkpoint Degradation with Exogenous Antigen Presentation to Boost Antitumor Immunity.

ACS chemical biology·2026

Same author

Traction Force Microscopy with DNA FluoroCubes.

Langmuir : the ACS journal of surfaces and colloids·2026

Search research articles

Related Experiment Video

Updated: Jan 6, 2026

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

Cell-Selective Targeting Chimeras (SelecTAC^B) for Membrane Protein Degradation on B Cells.

Zhenlin Yang^1,2,3, Jianfei Jiang^1,2,3, Yuhui Cao^1,3

¹Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University Beijing 100871, China.

Journal of the American Chemical Society

|September 26, 2025

Summary

Researchers developed SelecTAC^B, a novel chimera for targeted protein degradation. This technology selectively degrades membrane proteins on B cells, offering a new strategy for immune cell therapies.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Published on: October 15, 2016

Related Experiment Videos

Last Updated: Jan 6, 2026

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Published on: October 15, 2016

Area of Science:

Immunology
Molecular Biology
Biotechnology

Background:

Targeted protein degradation technologies (TPDs) enable precise control over protein levels.
Current TPDs lack cell-selectivity, especially for immune cell surface proteins.
Degrading specific proteins on target immune cells is a significant challenge.

Purpose of the Study:

To develop a cell-selective membrane protein degradation chimera (MPD) for B cells.
To leverage CD22 as a B cell-specific receptor for targeted degradation.
To establish a platform for selective protein degradation on immune cells.

Main Methods:

Designed SelecTAC^B, a chimera utilizing CD22 for B cell targeting.
Applied SelecTAC^B to human peripheral blood mononuclear cells (PBMCs).
Assessed degradation of target proteins (CD40, ICOSL) on B cells.

Main Results:

SelecTAC^B achieved targeted and cell-selective membrane protein degradation on B cells.
Degradation occurred without affecting protein expression in other immune cell types.
Inhibition of B cell functions was observed due to the degradation of key proteins.

Conclusions:

SelecTAC^B is an effective B cell-selective degradation platform.
This technology enables targeted membrane protein degradation on specific immune cells.
Offers a general strategy for developing cell-type selective therapies for immune cells.